Designing the next generation of clinical trials in intermediate AMD-a consensus driven, pragmatic, proof of concept early intervention study
Experimental Eye Research · 2025
DOI: 10.1016/j.exer.2025.110340 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Experimental Eye Research, 2025. Verfasst von Robyn H Guymer und 14 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia; Ophthalmology, Department of Surgery, The Univers…. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Macular Degeneration, Research Design. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Bristol, BrightFocus Foundation.
Abstract (Originalsprache)
A greater understanding of the pathophysiology of AMD has yielded potential therapeutic strategies for slowing vision loss. Structural imaging biomarkers and novel functional outcomes, both under intensive study as surrogate endpoints in AMD clinical trials, are new granular tools needed to assess disease progression and follow response to therapy. These advances have created, for the first time, the possibility to intervene early in AMD, and to measure success in a time frame feasible for clinical trials. At the 2024 Ryan Initiative for Macular Research (RIMR) meeting, a consensus was reached for design of a hypothetical, pragmatic, proof of concept, 24-month, early intervention study to determine the efficacy of an intervention in subjects with intermediate AMD (iAMD). Although further research is needed, using natural history cohorts and intervention trials to validate the proposed trial design and endpoints, this paper presents an AMD expert consensus framework for early AMD clinical trials, that we hope will also be useful for therapeutic developers and regulators. Viable clinical trial strategies are needed to develop treatments that slow the progression of AMD prior to the development of vision-threatening late AMD; this consensus document should aid in reaching this goal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia; Ophthalmology, Department of Surgery, The University of Melbourne, Melbourne, Australia. Electronic address: rhg@unimel…
- Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
- Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA.
- Pharmaceutical and Consumer Research and Development, Bausch and Lomb, Irvine, CA, USA.
- Genentech Genentech, Inc., South San Francisco, CA, USA.
- Ophthalmic Research Consultants, Switzerland.
Förderung
- University of Bristol
- BrightFocus Foundation
Zitieren
APA
Guymer, R. H., Rosenfeld, P. J., Ehlers, J. P., Attar, M., Chen, H., Ferris, F., Fujimoto, J. G., Ip, M., Pfau, M., Saßmannshausen, M., Shen, J., Zacks, D. N., van Zyl, T., Wu, Z., & Jaffe, G. J. (2025). Designing the next generation of clinical trials in intermediate AMD-a consensus driven, pragmatic, proof of concept early intervention study. Experimental Eye Research. https://doi.org/10.1016/j.exer.2025.110340
Vancouver
Guymer RH, Rosenfeld PJ, Ehlers JP, Attar M, Chen H, Ferris F, et al. Designing the next generation of clinical trials in intermediate AMD-a consensus driven, pragmatic, proof of concept early intervention study. Experimental Eye Research. 2025. doi:10.1016/j.exer.2025.110340
BibTeX
@article{Guymer2025,
author = {Guymer, Robyn H and Rosenfeld, Philip J and Ehlers, Justis P and Attar, Mayssa and Chen, Hao and Ferris, Frederick and Fujimoto, James G and Ip, Michael and Pfau, Maximilian and Saßmannshausen, Marlene and Shen, Jie and Zacks, David N and van Zyl, Tavé and Wu, Zhichao and Jaffe, Glenn J},
title = {Designing the next generation of clinical trials in intermediate AMD-a consensus driven, pragmatic, proof of concept early intervention study},
journal = {Experimental Eye Research},
year = {2025},
doi = {10.1016/j.exer.2025.110340}
}
EUVIMED